Breath Right guidance
This article was originally published in The Tan Sheet
Executive Summary
Abrupt end of cold/flu season in U.S. prompts firm to lower projections for fourth quarter results. Sales now expected in the $21 mil. to $23 mil. range, and the firm projects a loss of $.07 to $.02 per share. The marketer of Breath Right nasal strips and Vapor Shot personal vaporizer previously forecast sales in the $23.5 mil. to $25.5 mil. range and earnings of between breakeven and $.03 per share...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.